Alterations of thyroid function in overweight and obese children: An update

Jaivinder Yadav¹, Nimisha Jain², Devi Dayal¹

From ¹Department of Pediatrics, Pediatric Endocrinology and Diabetes Unit, ²Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Correspondence to: Dr. Devi Dayal, Department of Pediatrics, Pediatric Endocrinology and Diabetes Unit, Advanced Pediatrics Center, Postgraduate Institute of Medical Education and Research, Chandigarh – 160 012, India. Tel: 0091-172-2755657 (O)/0091-172-2772777 (R). Fax: 0091-172-2744401/2745078. E-mail: drdevidayal@gmail.com/dayal.devi@pgimer.edu.in

Received - 11 February 2018 Initial Review - 26 February 2018 Published Online - 21 March 2018

ABSTRACT

Background: Children with simple overweight and obesity may have alterations in the function of various endocrine organs. Abnormal function of the thyroid gland is seen in about one-fifth of children with obesity. The underlying mechanisms of obesity-associated thyroid dysfunction are still unclear, and hence, the specific treatment with levothyroxine (LT4) is controversial. This review discusses the causes of thyroid dysfunction and its management in pediatric obesity. Methods of Evidence Acquisition: The literature search for this narrative review was performed using international databases including PubMed/Medline, EMBASE, SCOPUS, and Google Scholar and relevant information was extracted from articles on thyroid dysfunction in obesity with an emphasis on the most recent studies. Results: The most common thyroid function abnormality in children with obesity is an isolated increase in thyroid-stimulating hormone (TSH) followed by minor changes in the ratios of triiodothyronine (T3) and thyroxine (T4). Several mechanisms have been proposed for the thyroid dysfunction in obesity, but none explains it fully, and hence, the clinical implications remain unclassified, and the specific treatment with levothyroxine is controversial. There are a few studies in children with obesity-related thyroid dysfunction and the effect of normalization of thyroid function on weight. However, there are limited data on the effect of normalization of thyroid function by either weight loss or levothyroxine (LT4) treatment on the various metabolic consequences closely associated with thyroid dysfunction in obesity. Conclusions: Further research is needed to elucidate the exact mechanisms of thyroid dysfunction in childhood obesity. In addition, larger studies are required to understand the beneficial effects of specific LT4 treatment on weight and on the other thyroid related metabolic derangements in childhood obesity, especially in view of the recent findings of induction of browning of white adipose tissue by thyroid hormones. Until new research establishes its benefits, specific LT4 treatment of thyroid dysfunction in childhood obesity should be avoided.

Key words: Children, Mechanisms, Obesity, Thyroid dysfunction, Treatment

Over the past few decades, childhood obesity has emerged as a major public health problem in the developed as well as developing countries [1]. It is associated with several physical, psychological, metabolic, and hormonal disturbances [2,3]. Children with obesity may manifest metabolic problems such as dyslipidemia, hypertension, impaired glucose tolerance, insulin resistance (IR), hypoferremia, polycystic ovarian syndrome, and non-alcoholic steatohepatitis which contribute to the risk of cardiovascular diseases and diabetes in later life [2-5]. These metabolic problems are attributed to the excess of adipose tissue, which works as an endocrine organ [6]. The hormonal problems due to obesity result in changes in the plasma concentrations, secretory patterns and clearance of various hormones [6]. Of the various hormonal disturbances observed in childhood obesity, thyroid dysfunction in the form of isolated hyperthyrotropinemia is the most common and is often regarded as an adaptive response to reduce body weight by increasing the metabolic rate [6]. The hyperthyrotropinemia usually reverses after weight loss and does not require any specific treatment [6,7]. However, patients are often initiated on levothyroxine (LT4) due to a widely prevalent belief among clinicians that LT4 treatment along with other obesity interventions results in normalization of body weight [6]. In this review, we discuss the current evidence on prevalence, mechanisms, and the current understanding of replacement therapy with LT4 in thyroid dysfunction due to simple obesity in children.

MAGNITUDE OF THE PROBLEM

The average prevalence of thyroid dysfunction in children and adolescents with obesity is about 14% (range, 9.2–22.2%) [7-12]. A higher prevalence of 17% and 22.2% has been reported from Germany and Israel, respectively [7,8], whereas studies from Nigeria and Denmark have reported a lower prevalence of about 10% [9,12]. In the two studies from Turkey, the prevalence of isolated hyperthyrotropinemia in childhood obesity was found to be 9.2% and 15.3% [10,11]. These studies on thyroid dysfunction have included preschool and school going children as well as adolescents with age range of 3–18 years (7–12). There is a
NORMAL METABOLISM OF THYROID HORMONES

The synthesis of thyroid hormones occurs through several enzymatic steps in the thyroid gland to secrete thyroxine (T4) as the main product. The more active triiodothyronine (T3) is mainly produced from deiodination of T4 in peripheral tissues. The homeostatic control involves multiple feedback loops and are in turn influenced by various genetic, physiological, pathological, and environmental factors; the end result of all these is to maintain serum T3 concentrations within the normal range. The classic feedback mechanism is the negative control exerted by T3 concentrations in plasma as well as in hypothalamus and pituitary on the expression and secretion of thyrotropin-releasing hormone (TRH) in the hypothalamus and thyroid-stimulating hormone (TSH) in the anterior pituitary. TSH regulates the function of thyroid gland and promotes the synthesis and activity of Type I deiodinases (D1) as a part of its actions. A similar effect is also exerted on the activity of Type II deiodinases (D2) in other peripheral tissues which have functional TSH receptors, such as brown adipose tissue (BAT) and bone [14]. However, the full thermogenic identity of the brown adipocyte is provided by the D2-dependent pathways. The BAT requires D2-dependent production of T3 for its function and adipogenesis [14]. Therefore, thyroid hormone-mediated activation of the BAT especially in adolescents and adults has a potential role in the treatment of obesity [14]. Several other feedback loops include the inhibition of its own secretion by TSH and peripheral regulation of thyroid hormones that control bioavailability and cellular bioactivity.

PRINCIPAL EFFECTS OF ABNORMAL THYROID FUNCTION ON BODY WEIGHT

A close relationship exists between thyroid function and body composition. Thyroid hormones are involved in the regulation of basal metabolism and thermogenesis and have a significant role in lipid and glucose metabolism, food intake, and fat oxidation [15]. Thyroid dysfunction, therefore, affects body weight and composition, body temperature, and resting energy expenditure (REE), and total EE independent of physical activity [15]. In adults, untreated subclinical hypothyroidism may lead to significant changes in body weight and is considered as a risk factor for overweight and obesity [13]. Even minor variations in serum TSH due to changes in dosage of levothyroxine during treatment of hypothyroidism are associated with significant changes in REE [16]. There is, however, a scarcity of data regarding the extent of weight gain due to thyroid dysfunction and the extent of weight loss attributable to LT4 treatment in hypothyroidism [13].

PROPOSED MECHANISMS OF THYROID DYSFUNCTION IN OBESITY

Several mechanisms have been proposed for the alterations in thyroid function in obese patients. However, it is not established whether these alterations in thyroid function are primary or secondary to obesity [6,13]. Changes in thyroid function are primarily driven by the dysfunction of adipose tissue as weight loss is associated with reversal or mitigation of thyroid dysfunction [17]. Conversely, longitudinal studies have shown that even minor thyroid dysfunction such as isolated TSH increase leads to weight gain and are associated with a significant risk of becoming obese [6,18]. The proposed mechanisms for thyroid dysfunction in obesity are briefly discussed below. A schematic presentation of the main mechanisms is given in Fig. 1.

Adaptive Response to Increase EE

Thyroid hormones play an important role in energy metabolism and ATP turnover, especially in inducing thermogenesis by stimulating energy uncoupling protein (UCP) [19]. This can partly explain the commonly proposed mechanism that the increase in TSH and T3 in obese children is an adaptive process to increase EE and minimize further weight gain [20]. The mechanism is also supported by clinical observations that minor changes in serum TSH during treatment of hypothyroidism cause significant changes in REE [16]. However, the increase in REE may also be due to a concomitant increase in fat-free mass in obese individuals [21]. Furthermore, recent data suggests that there is no association between EE and concentrations of serum TSH, and free T3 and T4 in euthyroid obese individuals [22]. This may be due to the impaired thyroid hormone action to induce thermogenesis in obese individuals. The adipose tissue especially the visceral adipose tissue is shown to have decreased expression of thyroid hormone receptors, deiodinases, adrenergic receptors, and UCP in patients with obesity [23]. The reduced reactivity to hormonal and adrenergic stimuli in adipose tissues leads to a lower potential to activate thermogenesis in these patients [23]. With weight loss, the concentrations of T3 and TSH also decrease and cause a decrease in REE as well as TEE which partly explains the difficulties in maintaining the weight loss [7].

Hyperleptinemia Due to Increased Leptin Secretion by Adipose Tissue

Leptin is mainly produced by adipocytes and has a major role in food intake and energy storage [24,25]. It is involved in the regulation of body weight through inhibition of food intake and stimulation of EE and locomotor activity. The serum concentrations of leptin increase proportionally to the increase in body adiposity [24,25]. The consequent hyperleptinemia influences the hypothalamic-pituitary-thyroid axis by promoting TRH expression and synthesis in paraventricular hypothalamic nucleus by a direct action and in arcuate nucleus indirectly leading to an increase in TSH secretion by the pituitary gland [25]. Leptin also activates proopiomelanocortin neurons and inhibits Agouti-related protein and neuropeptide Y neurons in the arcuate nucleus. As a result, the production of n-melanocyte stimulating hormone increases which stimulates the expression of TRH in hypothalamic neurons by binding to the melanocortin 4 receptor [26]. Leptin also induces the expression of enzymes involved in proteolytic...
cleavage of pro-TRH to its biologically active form [25]. Leptin may also act directly on pituitary to increase TSH secretion as leptin receptors are found in the pituitary gland as well. The net result of all these actions of leptin on hypothalamic-pituitary axis is the increased production of TSH from the pituitary. The increased TSH, in turn, may stimulate leptin secretion (TSH helps in differentiation of preadipocytes into adipocytes) through its receptors on the adipose tissue thus creating a vicious cycle of hyperleptinemia and hyperthyrotropinemia [27]. Recent studies also indicate the existence of a complex positive feedback mechanism between these two hormones [28].

In addition to its actions on the hypothalamic-pituitary axis, leptin also influences the metabolism of thyroid hormones by altering the activity of deiodinases in various tissues; increase in D1 activity in the liver, kidney, and thyroid, and reduction of D2 activity in BAT and the pituitary gland [25,28]. Hence, while leptin seems to increase the local production of T3 in the adipose tissue it should be remembered that the reduced expression of thyroid hormone receptors in obesity may hamper the local actions of T3.

**Resistance to Thyroid Hormones**

Obesity may induce a state of resistance similar to genetic form of thyroid hormone resistance. The changes in thyroid hormone receptors (TR) are primarily observed in the adipose tissue but are also present in other tissues [29]. A relative pituitary resistance to T3 resulting in increased concentrations of both TSH and T3 is also observed in obesity [24]. The decreased tissue responsiveness explains the usual findings of increased TSH and T3 in an attempt to overcome peripheral resistance [29]. However, recent research in this regard has shown conflicting results. The expression of TSH receptor and TRα1 in adipose tissue was found to be inversely correlated with body mass index (BMI) [29]. The increase in the severity of obesity increased the peripheral resistance to thyroid hormones leading to an increase in concentrations of TSH and T3, and weight loss increased the expression of receptors and a consequent fall in hormone concentrations [29]. Similar findings of reduced expression of TRs in adipose tissue were observed in another study [23]. In contrast to these two studies, a recent study showed increased TSH receptor expression in adipocytes of overweight individuals and a trend toward increased expression of this receptor with increasing BMI [30]. The discrepancies in the findings of these studies may be related to the location of the adipose tissue studied or an indication of the complexity of regulatory actions of thyroid hormones [6].

**Increased Concentrations of Inflammatory Cytokines**

Obesity is characterized by chronic low grade inflammation as evidenced by increase in concentrations of high sensitivity C-reactive protein and other inflammatory cytokines [3,31]. A positive correlation has indeed been documented between markers of inflammation and thyroid function and morphology in obese subjects [31]. The underlying mechanism is inhibition of mRNA expression of sodium/iodide symporter by inflammatory cytokines such as tumor necrosis factor α, interleukin-1, and interleukin-6, resulting in reduced iodide uptake in thyroid cells [32]. These adipokines may also induce morphological abnormalities in thyroid gland [24]. The role of chronic inflammation in the regulation of deiodinases in different tissues is also speculated but the mechanisms are unclear at present [33].

**Influence of Thyroid Autoimmunity**

Thyroid autoimmunity may lead to the common finding of subclinical hypothyroidism in obesity [34]. The frequent finding of a hypoechochogenic pattern on thyroid ultrasonography in obese patients was thought to be the manifestation of a seronegative autoimmune thyroid disease (AITD) that may precede the generation of thyroid autoantibodies [34]. Another study concluded that obesity is a risk factor for thyroid autoimmunity and main cause of acquired thyroid failure in obesity [35]. Leptin was suggested as main determinant of autoimmunity, leptin concentrations were associated with AITD independent of bio-anthropometric variables [35]. This study also noted an increased the prevalence of hypothyroidism and thyroid autoantibodies in obese subjects as compared to controls [35]. A greater prevalence of thyroid autoantibodies in obese children as compared to their controls have also been observed in other studies [36-38]. However, not all patients with autoantibody positivity show evidence of thyroid dysfunction; a majority of patients with obesity-related thyroid dysfunction do not have autoantibodies [36-39]. Furthermore, observations in morbidly obese patients suggest that thyroid autoimmunity may not be a major cause of hypothyroidism [40]. The antibody positivity rate was found to be much lower in obese patients with untreated hypothyroidism as compared to controls (32.1 vs. 66.1%) in this study [40]. Thus, the role of thyroid autoimmunity in inducing thyroid dysfunction in obesity remains unresolved.

**Role of IR**

IR is commonly observed in patients with simple overweight and obesity [41] similar to patients with secondary obesity [42,43]. The hyperinsulinemia stimulates leptin release from adipocytes leading to hyperleptinemia which is closely associated with features of IR [44,45]. Although a positive association between markers of IR and serum TSH has been observed, the underlying mechanisms are not clear [44]. The hypothalamic-pituitary-thyroid axis may be affected by IR in different ways. IR may reduce D2 activity in thyrotrophs causing tissue hypothyroidism and an increased TSH synthesis [46]. The increased TSH may also stimulate the synthesis of inflammatory cytokines by adipocytes and promote IR [17]. The increase in T3 concentrations is also positively associated with IR [47]. Although T3 is known to regulate the metabolic processes of gluconeogenesis, insulin secretion and function, the underlying mechanisms of how it influences the glucose homeostasis are unclear [6].
CURRENT CONTROVERSIES RELATED TO LT4 TREATMENT OF THYROID DYSFUNCTION

In the wake of current understanding that thyroid dysfunction may lead to several other metabolic and endocrine alterations in obesity, specific therapy with LT4 appears desirable, at least theoretically. There is also a widely prevalent belief among clinicians that LT4 treatment may be beneficial in normalization of body weight [24]. The specific treatment may also help overcoming the difficulties in maintaining the weight loss by keeping the REE and TEE higher which usually fall as a result of fall in the concentrations of T3 and TSH after weight loss [7]. However, clinical studies of LT4 supplementation in obesity-associated thyroid dysfunction have failed to demonstrate beneficial effects on body weight [48,49]. In a study in children with acquired hypothyroidism, LT4 treatment showed no effect on body weight and BMI even after normalization of TSH concentrations [50]. A systematic review concluded that there is not enough data on the effectiveness of LT4 therapy to enhance weight loss and subclinical hyperthyroidism may occur as a complication of such therapy [51]. While the data on LT4 supplementation to treat thyroid dysfunction in obesity remains scarce, there are several studies which have shown a normalization of this dysfunction with weight loss only [7,24,52-55]. The findings and limitations of the major interventional studies are summarized in Table 1. The normalization of TSH after weight loss without LT4 therapy has also been shown to have beneficial effects on insulin sensitivity and leptin levels [55]. The European Thyroid Association and several pediatric thyroid societies recommend that the decision to initiate LT4 treatment in children with TSH <10 mU/L and normal T4 concentrations should be taken on an individual basis as there is insufficient evidence for the need for such treatment [56,57].

| Authors, year, country and reference No | Study subjects (mean age) | Results and conclusions | Limitations |
|----------------------------------------|---------------------------|-------------------------|-------------|
| Reinehr T et al., 2002, Germany (52)   | 118 obese and 107 controls (10.9±2.9 yr) | 55 obese children who achieved weight reduction showed normalization of T3 and T4 but not TSH, without use of thyroxine | Small sample size and observation period |
| Reinehr T et al., 2006, Germany (7)   | 246 obese children (9.5±2.0 yr) and 71 controls | Hyperthyrotropinemia improved in 49 obese children who showed significant weight loss after 1 yr intervention based on exercise, behavior therapy, and nutrition education | None |
| Eliakim A et al., 2006, Israel (49)  | 41 obese children (10.6±0.2 yr) and 15 received thyroxine | Hyperthyrotropinemia improved in majority of children who participated in weight reduction intervention, irrespective of thyroxine use | Small sample size |
| Grandone A et al., 2010, Italy (54) | 64 of 398 children (10.3±2.6 yr) participated in weight reduction program | 23 out of 64 children showed weight loss and concomitant reduction of hyperthyrotropinemia indicating no requirement of additional levothyroxine | Small sample size |
| Marras V et al., 2010, Italy (53) | 43 out of 109 obese children with thyroid dysfunction underwent lifestyle intervention | The thyroid hormone levels of obese children who underwent weight reduction program for 6 months were compared with normal weight controls. Moderate weight loss over 6 months improved thyroid dysfunction without use of thyroxine in obese children | Selection of non-obese controls |
| Matusik P et al., 2015, Poland (48) | 51 children (10.0±3.1 yr) received thyroxine | Normalisation of TSH was similar in children treated by dietary-behavioral management as compared to those given additional levothyroxine | Retrospective design |

Figure 1: Proposed mechanisms for alterations in thyroid hormone levels in obesity. (a) Increased leptin secretion by adipose tissue stimulates hypothalamus to increase thyrotropin releasing hormone (TRH) which increases thyroid-stimulating hormone (TSH) from pituitary. Leptin modulates thyroid gland’s responsiveness to TSH, inhibits iodide uptake and expression of sodium/iodide symporter and thyrogbulin. Leptin also increases the activity of deiodinases (D1). (b) There is a change in the activity of deiodinases (D1, D2, and D3) and receptors which promote a state of thyroid hormone resistance. (c) The increased adipokines released by the adipose tissue affect thyroid gland as well as deiodinases. (d) Insulin resistance may reduce deiodinase activity (D2) and increase TSH production from the pituitary. (e) The net result is the alterations in thyroid hormones concentrations leading to changes in energy expenditure and metabolic regulations of body tissues.
**RECOMMENDATIONS FOR FUTURE RESEARCH**

There are a number of studies on the effect of weight loss on thyroid dysfunction in childhood obesity [7,24,52-54]. However, there is limited data on the effect of weight loss on different metabolic alterations such as hyperleptinemia, IR, and dyslipidemia in obesity which may have a link with the thyroid dysfunction [7,55]. In particular, the effect of specific treatment of thyroid dysfunction with LT4 on these metabolic changes has not been evaluated. There is, thus, a need for acquisition of more data to draw conclusions about the beneficial effects of LT4 supplementation in childhood obesity. A recent study has suggested that thyroid hormones induce browning of white adipose tissue and that this mechanism is mediated through central effects of these hormones on energy balance [58]. This beneficial effect of LT4 treatment in childhood obesity also needs exploration in future studies.

**CONCLUSIONS**

Thyroid dysfunction occurs commonly in children with simple overweight and obesity. However, the underlying mechanisms of thyroid dysfunction are poorly understood at present. Several metabolic alterations such as increased leptin concentrations, lipid concentrations, and IR may have a link with thyroid dysfunction. The thyroid dysfunction usually reverses after weight loss, and hence, specific therapy with LT4 is considered inappropriate. However, the data on the effects of specific LT4 therapy in childhood obesity, other than on weight and body mass index, are scarce. Further research should focus on the effects of normalization of thyroid function either by weight loss or specific LT4 treatment on the various metabolic abnormalities commonly occurring with thyroid dysfunction in childhood obesity.

**REFERENCES**

1. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the global burden of disease study 2013. Lancet 2014;384:766-81.

2. Sanders RH, Han A, Baker JS, Cobley S. Childhood obesity and its physical and psychological co-morbidities: A systematic review of Australian children and adolescents. Eur J Pediatr 2015;174:715-46.

3. Dayal D, Jain H, Attri SW, Bharti B, Bhatta AK. Relationship of high sensitivity C-reactive protein levels to anthropometric and other metabolic parameters in Indian children with simple overweight and obesity. J Clin Diagn Res 2014;8:PC05-8.

4. Siyaram D, Bhatta P, Dayal D, Bhatta AK, Marathe R. Hypoferrimetric state in overweight and obese children. Indian Pediatr 2018;55:72-3.

5. Kamble R, Sodhi KS, Thapa BR, Saxena AK, Bhatta A, Dayal D, et al. Liver acoustic radiation force impulse (ARFI) in childhood obesity: Comparison and correlation with biochemical markers. J Ultrasound 2017;20:33-42.

6. Fontenelle LC, Feitosa MM, Severo JS, Freitas TE, Morais JB, Torres-Leal FL, et al. Thyroid function in human obesity: Underlying mechanisms. Horm Metab Res 2016;48:787-94.

7. Reinehr T, de Sousa G, Andler W. Hyperthyrotropinemia in obese children is reversible after weight loss and is not related to lipids. J Clin Endocrinol Metab 2006;91:3088-91.

8. Shalitin S, Yakobovitch-Gavan M, Phillip M. Prevalence of thyroid dysfunction in obese children and adolescents before and after weight reduction and its relation to other metabolic parameters. Horm Res 2009;71:155-61.

9. Emokpae MA, Adeleke SI, Uwumarangie HO. Subclinical hypothyroidism in childhood obesity and its correlation with lipoproteins. Afr J Med Med Sci 2011;40:361-5.

10. Bas VN, Aycan Z, Ağlıdoğlu SY, Kendirci HN. Prevalence of hyperthyrotropinemia in obese children before and after weight loss. Eat Weight Disord 2013;18:87-90.

11. Uluvar T, Anik A, Catli G, Esen I, Abaci A, Büyükgözü A, et al. Isolated hyperthyrotropinemia in childhood obesity and its relation with metabolic parameters. J Endocrinol Invest 2014;37:799-804.

12. Dahl M, Ohrt JD, Fonvig CE, Kloppenborg JT, Pedersen O, Hansen T, et al. Subclinical hypothyroidism in Danish lean and obese children and adolescents. J Clin Res Pediatr Endocrinol 2017;9:8-16.

13. Sanyal D, Raychaudhuri M. Hyperthyroidism and obesity: An intriguing link. Indian J Endocrinol Metab 2016;20:554-7.

14. Draman MS, Steehman M, Scott-Coobses D, Dayan CM, Rees DA, Ludgate M, et al. The role of thyroid tropin receptor activation in Adipogenesis and modulation of fat phenotype. Front Endocrinol (Lausanne) 2017;8:83.

15. Bicanto AC, McAninch EA. The role of thyroid hormone and brown adipose tissue in energy homeostasis. Lancet Diabetes Endocrinol 2013;1:250-8.

16. Knudsen N, Laurberg P, Rasmussen LB, Bålow I, Perrild H, Ovesen L, et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab 2005;90:4019-24.

17. Muscogiuri G, Sorice GP, Mezza T, Piroletta A, Lassandro AP, Pirronti T, et al. High-normal TSH values in obesity: Is it insulin resistance or adipose tissue’s guilt? Obesity (Silver Spring) 2013;21:101-6.

18. Bjergvld L, Jorgensen T, Perrild H, Laurberg P, Krejbjerg A, Ovesen L, et al. Thyroid function and body weight: A community-based longitudinal study. PLoS One 2014;9:e93515.

19. Vaitkus JA, Farrar JS, Celi FS. Thyroid hormone mediated modulation of energy expenditure. Int J Mol Sci 2015;16:16158-75.

20. Pacilio L, Anania C, Ferraro F, Andreoli GM, Chiesa C. Thyroid function in childhood obesity and metabolic comorbidities. Clin Chim Acta 2012;413:396-405.

21. Cameiro IP, Elliott SA, Siervo M, Padwal R, Bertoli S, Battezzati A, et al. Is obesity associated with altered energy expenditure? Adv Nutr 2016;7:476-87.

22. Spadafranca A, Cappelletti C, Leone A, Vignati L, Battezzati A, Bedogni G, et al. Relationship between thyroid hormones, resting energy expenditure and cardiometabolic risk factors in euthyroid subjects. Clin Nutr 2015;34:674-8.

23. Kurylowicz A, Jonas M, Lisik W, Jonas M, Wierzbicki Z, et al. Obesity is associated with a decrease in expression but not with the hypermethylation of thermogenesis related genes in adipose tissues. J Transl Med 2015;13:31.

24. Witkowska-Śędęk E, Kucharska A, Rumieńska M, Pyrzyk B. Thyroid dysfunction in obese and overweight children. Endokrynol Pol 2017;68:54-60.

25. Feldt RU. Thyroid and leptin. Thyroid 2007;17:413-9.

26. Nilni EA. Regulation of the hypothalamic thyrotropin releasing hormone (TRH) neuron by neuronal and peripheral inputs. Front Neuroendocrinol 2010;31:134-56.

27. Duntas LH, Biondi B. The interconnections between obesity, thyroid function, and autoimmunity: The multifold role of leptin. Thyroid 2013;23:646-53.

28. Ortega FJ, Jílková ZM, Moreno-Navarrete JM, Pavelka S, Rodríguez-Hernosa JL, Kopecký J, et al. Type I iodothyronine 5'-deiodinase mRNA and activity is increased in adipose tissue of obese subjects. Int J Obes (Lond) 2012;36:320-4.

29. Nannipieri M, Cecchetti F, Anselmino M, Camastro S, Niccolini P, Lamacchia M, et al. Expression of thyrotropin and thyroid hormone receptors in adipose tissue of patients with morbid obesity and/or type 2 diabetes: Effects of weight loss. Int J Obes (Lond) 2009;33:1001-6.

30. Lu S, Guan Q, Liu Y, Wang H, Xu W, Li X, et al. Role of extrathyroidal TSHR expression in adipocyte differentiation and its association with obesity. Lipids Health Dis 2012;11:17.

31. Chen H, Zhang H, Tang W, Xi Q, Liu X, Duan Y, et al. Thyroid function and morphology in overweight and obese children and adolescents in a Chinese population. J Pediatr Endocrinol Metab 2013;26:489-96.

32. Aijan RA, Watson PF, Findlay C, Metcalfe RA, Crisp M, Ludgate M, et al. The sodium iodide symporter gene and its regulation by cytokines found in
autoimmunity. J Endocrinol 1998;158:351-8.

33. Kwakkel J, Survetseva OV, de Vries EM, Stap J, Fliers E, Boelen A, et al. A novel role for the thyroid hormone-activating enzyme Type 2 deiodinase in the inflammatory response of macrophages. Endocrinology 2014;155:2725-34.

34. Reinehr T. Thyroid function in the nutritionally obese child and adolescent. Curr Opin Pediatr 2011;23:415-20.

35. Marzullo P, Minocci A, Tagliaferri MA, Guzzaloni G, Di Blasio A, De Medicis C, et al. Investigations of thyroid hormones and antibodies in obesity: Leptin levels are associated with thyroid autoimmunity independent of bioanthropometric, hormonal, and weight-related determinants. J Clin Endocrinol Metab 2010;95:3965-72.

36. Stichel H, l’Allemand D, Grütters A. Thyroid function and obesity in children and adolescents. Horm Res 2000;54:14-9.

37. Bhowmick SK, Dasari G, Levens KL, Rettig KR. The prevalence of elevated serum thyroid-stimulating hormone in childhood/adolescent obesity and of autoimmune thyroid diseases in a subgroup. J Natl Med Assoc 2007;99:773-6.

38. García GE, Vázquez-López MA, García-Fuentes E, Galera-Martínez R, Gutiérrez-Repiso C, García-Escobar I, et al. Thyroid function and thyroid autoimmunity in relation to weight status and cardiovascular risk factors in children and adolescents: A population-based study. J Clin Res Pediatr Endocrinol 2016;8:157-62.

39. Radetti G, Kleon W, Buzzi F, Crivellaro C, Pappalardo L, di Iorgi N, et al. Thyroid function and structure are affected in childhood obesity. J Clin Endocrinol Metabol 2008;93:4749-54.

40. Rotondi M, Leporati P, La Manna A, Pirali B, Mondello T, Fonte R, et al. Raised serum TSH levels in patients with morbid obesity: Is it enough to diagnose subclinical hypothyroidism? Eur J Endocrinol 2009;160:403-8.

41. Levy-Marchal C, Arslanian S, Cutfield W, Sinaiko A, Druet C, Marcovecchio ML, et al. Insulin resistance in children: Consensus, perspective, and future directions. J Clin Endocrinol Metab 2010;95:5189-98.

42. Dayal D, Seetharaman K, Panigrahi I, Balasubramaniam M, Agarwal A. Severe early onset obesity due to a novel missense mutation in exon 3 of the leptin gene in an infant from northwest india. J Clin Res Pediatr Endocrinol 2017.

43. Dayal D, Muthuvel B, Sodhi KS. Obesity as the presenting feature of sellar-suprasellar tuberculoma. Indian J Endocrinol Metab 2018;22:176-7.

44. Yadav A, Kataria MA, Saini V, Yadav A. Role of leptin and adiponectin in insulin resistance. Clin Chim Acta 2013;417:80-4.

45. Tenneti N, Dayal D, Sharda S, Panigrahi I, Didi M, Attri SV, et al. Concentrations of leptin, adiponectin and other metabolic parameters in non-obese children with down syndrome. J Pediatr Endocrinol Metab 2017;30:831-7.

46. Kullmann S, Heni M, Hallischmid M, Fritsche A, Preissl H, Häring HU, et al. Brain insulin resistance at the crossroads of metabolic and cognitive disorders in humans. Physiol Rev 2016;96:1169-209.

47. Tarcin O, Abanouo GB, Yazici D, Tarcin O. Association of metabolic syndrome parameters with TT3 and FT3/FT4 ratio in obese Turkish population. Metab Syndr Relat Disord 2012;10:137-42.

48. Matusik P, Gawlik A, Januszek-Trzciakowska A, Malecka-Tendera E. Isolated subclinical hyperthyrotropinemia in obese children: Does levothyroxine (LT4) improve weight reduction during combined behavioral therapy? Int J Endocrinol 2015;2015:792509.

49. Eliakim A, Barzilai M, Wolach B, Nemet D. Should we treat elevated thyroid stimulating hormone levels in obese children and adolescents? Int J Pediatr Obes 2006;1:217-21.

50. Lomenick JP, El-Sayyid M, Smith WJ. Effect of levo-thyroxine treatment on weight and body mass index in children with acquired hypothyroidism. J Pediatr 2008;152:96-100.

51. Kaptein EM, Beale E, Chan LS. Thyroid hormone therapy for obesity and nonthyroidal illnesses: A systematic review. J Clin Endocrinol Metab 2009;94:3663-75.

52. Reinehr T, Andler W. Thyroid hormones before and after weight loss in obesity. Arch Dis Child 2002;87:320-3.

53. Marras V, Casini MR, Pilia S, Carta D, Civolani P, Porcu M, et al. Thyroid function in obese children and adolescents. Horm Res Paediatr 2010;73:193-7.

54. Grandone A, Santoro N, Coppola F, Calabro P, Perrone L, Del Giudice EM, et al. Thyroid function derangement and childhood obesity: An Italian experience. BMC Endocr Disord 2010;10:8.

55. Aebeleri I, Jung A, Murer SB, Wildhaber J, Wildhaber-Brooks J, Knöpfli BH, et al. During rapid weight loss in obese children, reductions in TSH predict improvements in insulin sensitivity independent of changes in body weight or fat. J Clin Endocrinol Metab 2010;95:5412-8.

56. Lazarus J, Brown RS, Daumerie C, Hubalewska-Dydejczyk A, Negro R, Vaidya B. 2014 European thyroid association guidelines for the management of subclinical hypothyroidism in pregnancy and in children. Eur Thyroid J 2014;3:76-94.

57. Dayal D, Prasad R. Congenital hypothyroidism: Current perspectives. Res Rep Endocr Disord 2015;5:91-102.

58. Martínez-Sánchez N, Moreno-Navaarrete JM, Contreras C, Rial-Pensado E, Ferno J, Nogueiras R, et al. Thyroid hormones induce browning of white fat. J Endocrinol 2017;232:351-62.

Funding: None; Conflict of Interest: None Stated.

How to cite this article: Yadav J, Jain N, Dayal D. Alterations of thyroid function in overweight and obese children: An update. Indian J Child Health. 2018; 5(3):145-150.